KR20030007829A - 트리아졸로(4,5-d)피리미딘 화합물의 신규 결정형 및비결정형 - Google Patents
트리아졸로(4,5-d)피리미딘 화합물의 신규 결정형 및비결정형 Download PDFInfo
- Publication number
- KR20030007829A KR20030007829A KR1020027016379A KR20027016379A KR20030007829A KR 20030007829 A KR20030007829 A KR 20030007829A KR 1020027016379 A KR1020027016379 A KR 1020027016379A KR 20027016379 A KR20027016379 A KR 20027016379A KR 20030007829 A KR20030007829 A KR 20030007829A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- solvent
- mixture
- water
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (32)
- 실질적으로 결정형인 하기 화학식 I의 화합물.<화학식 I>
- 제1항에 있어서, 실질적으로 무수 형태로 존재하는 화학식 I의 화합물.
- 제1항에 있어서, 5.3°(±0.1°), 20.1°(±0.1°), 20.7°(±0.1°), 21.0°(±0.1°) 및 21.3°(±0.1°) 2θ에서 고강도의 특정 피이크를 함유하는 X-선 분말 회절 패턴에 의해 특징지워지는 화학식 I의 화합물.
- 제1항 또는 3항에 있어서, 5.3°(±0.1°), 8.0°(±0.1°), 9.6°(±0.1°), 13.9°(±0.1°), 15.3°(±0.1°), 20.1°(±0.1°), 20.7°(±0.1°), 21.0°(±0.1°), 21.3°(±0.1°), 26.2°(±0.1°) 및 27.5°(±0.1°) 2θ에서 특정 피이크를 함유하는 X-선 분말 회절 패턴에 의해 특징지워지는 화학식 I의 화합물.
- 제1항, 3항 또는 4항 중 어느 한 항에 있어서, 146 - 152 ℃ 범위 내의 용융 개시점을 갖는 시차 주사 열량측정 곡선에 의해 특징지워지는 화학식 I의 화합물.
- 제1항에 있어서, 5.5°(±0.1°), 13.5°(±0.1°), 18.3°(±0.1°), 22.7°(±0.1°) 및 24.3°(±0.1°) 2θ에서 고강도의 특정 피이크를 함유하는 X-선 분말 회절 패턴에 의해 특징지워지는 화학식 I의 화합물.
- 제1항 또는 6항에 있어서, 5.5°(±0.1°), 6.8°(±0.1°), 10.6°(±0.1°), 13.5°(±0.1°), 14.9°(±0.1°), 18.3°(±0.1°), 19.2°(±0.1°), 22.7°(±0.1°), 24.3°(±0.1°) 및 27.1°(±0.1°) 2θ에서 특정 피이크를 함유하는 X-선 분말 회절 패턴에 의해 특징지워지는 화학식 I의 화합물.
- 제1항, 6항 또는 7항 중 어느 한 항에 있어서, 136 - 139 ℃ 범위 내의 용융 개시점을 갖는 시차 주사 열량측정 곡선에 의해 특징지워지는 화학식 I의 화합물.
- 제1항에 있어서, 14.0°(±0.1°), 17.4°(±0.1°), 18.4°(±0.1°), 21.4°(±0.1°) 및 24.1°(±0.1°) 2θ에서 고강도의 특정 피이크를 함유하는 X-선 분말 회절 패턴에 의해 특징지워지는 화학식 I의 화합물.
- 제1항 또는 9항에 있어서, 5.6°(±0.1°), 12.5°(±0.1°), 14.0°(±0.1°), 17.4°(±0.1°), 18.4°(±0.1°), 21.4°(±0.1°), 22.2°(±0.1°), 22.9°(±0.1°), 24.1°(±0.1°) 및 24.5°(±0.1°) 2θ에서 특정 피이크를 함유하는 X-선 분말 회절 패턴에 의해 특징지워지는 화학식 I의 화합물.
- 제1항, 9항 또는 10항 중 어느 한 항에 있어서, 127 - 132 ℃ 범위 내의 용융 개시점을 갖는 시차 주사 열량측정 곡선에 의해 특징지워지는 화학식 I의 화합물.
- 제1항에 있어서, 4.9°(±0.1°), 9.2°(±0.1°), 11.6°(±0.1°), 15.6°(±0.1°) 및 16.4°(±0.1°) 2θ에서 고강도의 특정 피이크를 함유하는 X-선 분말 회절 패턴에 의해 특징지워지는 화학식 I의 화합물.
- 제1항 또는 12항에 있어서, 4.9°(±0.1°), 6.0°(±0.1°), 9.2°(±0.1°), 11.6°(±0.1°), 12.8°(±0.1°), 15.6°(±0.1°), 16.4°(±0.1°), 17.2°(±0.1°) 및 18.1°(±0.1°) 2θ에서 특정 피이크를 함유하는 X-선 분말 회절 패턴에 의해 특징지워지는 화학식 I의 화합물.
- 제1항, 12항 또는 13항 중 어느 한 항에 있어서, 약 139 ℃에서 용융 개시점을 갖는 시차 주사 열량측정 곡선에 의해 특징지워지는 화학식 I의 화합물.
- 실질적으로 무수 형태인 화학식 I의 화합물.
- 수화물 형태인 화학식 I의 화합물.
- 제6항 내지 8항 중 어느 한 항에 청구된 화학식 I의 화합물 및 제9항 내지 11항 중 어느 한 항에 청구된 화학식 I의 화합물의 혼합물.
- 화학식 I의 화합물이 저급 알킬 아세테이트, 저급 알킬 알코올, 지방족 및 방향족 탄화수소, 디알킬 에테르, 디알킬 케톤, 아세토니트릴, 물 또는 그의 혼합물로 이루어진 군에서 선택된 용매로부터 결정화되는, 제1항에 청구된 화합물의 제조 방법.
- 제18항에 있어서, 용매가 에탄올, 에틸 아세테이트, 이소-프로판올, 이소-옥탄, 아세토니트릴, 물 또는 그의 혼합물로 이루어진 군에서 선택되는 방법.
- 제19항에 있어서, 용매가 메탄올 및 물의 혼합물, 에탄올, 에틸 아세테이트, 에탄올 및 물의 혼합물, 이소-프로판올 및 물의 혼합물, 에틸 아세테이트 및 이소-옥탄의 혼합물, 및 아세토니트릴로 이루어진 군에서 선택되는 방법.
- 용매가 메탄올 및 물의 혼합물인 제18항 내지 20항 중 어느 한 항에 따른, 제3항 내지 5항 중 어느 한 항에 청구된 화합물의 제조 방법.
- 종결정을 이용하는 제3항 내지 5항 중 어느 한 항에 청구된 화합물의 제조 방법.
- 제22항에 있어서, 종결정이 제6항 내지 8항 중 어느 한 항에 청구된 화합물을 용융시킴으로써 제조되는 방법.
- 용매가 에틸 아세테이트인 제18항 내지 20항 중 어느 한 항에 따른, 제6항 내지 8항 중 어느 한 항에 청구된 화합물의 제조 방법.
- 용매가 알코올인 제18항 내지 20항 중 어느 한 항에 따른, 제9항 내지 11항 중 어느 한 항에 청구된 화합물의 제조 방법.
- 화학식 I의 화합물을 5 내지 65 ℃의 온도에서 IPA/물 용매계에서 슬러리화하는 것을 포함하는, 제9항 내지 11항 중 어느 한 항에 청구된 화합물의 제조 방법.
- 용매가 아세토니트릴인 제18항 내지 20항 중 어느 한 항에 따른 방법을 포함하는, 제12항 내지 14항 중 어느 한 항에 청구된 화합물의 제조 방법.
- 의약으로서 사용하기 위한 제1항 내지 17항 중 어느 한 항에 청구된 화합물.
- 제1항 내지 17항 중 어느 한 항에 청구된 화합물을 제약학적으로 허용되는 보조제, 희석제 또는 담체와 함께 포함하는 제약 조성물.
- 관상 동맥, 대뇌혈관 또는 말초 혈관 질환을 가진 환자에서의 동맥 혈전성 합병증을 예방하기 위한 제1항 내지 17항 중 어느 한 항에 청구된 화합물을 포함하는 제약 조성물.
- 관상 동맥, 대뇌혈관 또는 말초 혈관 질환을 가진 환자에서의 동맥 혈전성 합병증을 예방하기 위한 의약 제조에서의 제1항 내지 17항 중 어느 한 항에 청구된 화합물의 용도.
- 치료학적 유효량의 제1항 내지 17항 중 어느 한 항에 청구된 화합물을 관상 동맥, 대뇌혈관 또는 말초 혈관 질환을 앓고 있거나 또는 앓기 쉬운 대상에게 투여하는 것을 포함하는, 그러한 질환을 가진 환자에서 동맥 혈전성 합병증을 치료 또는 예방하는 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0013407.2A GB0013407D0 (en) | 2000-06-02 | 2000-06-02 | Forms of a chemical compound |
GB0013407.2 | 2000-06-02 | ||
PCT/SE2001/001239 WO2001092262A1 (en) | 2000-06-02 | 2001-05-31 | New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030007829A true KR20030007829A (ko) | 2003-01-23 |
KR100781864B1 KR100781864B1 (ko) | 2007-12-05 |
Family
ID=9892841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027016379A KR100781864B1 (ko) | 2000-06-02 | 2001-05-31 | 트리아졸로(4,5-d)피리미딘 화합물의 신규 결정형 및비결정형 |
Country Status (36)
Country | Link |
---|---|
US (3) | US20030181469A1 (ko) |
EP (3) | EP2292622A1 (ko) |
JP (3) | JP5036947B2 (ko) |
KR (1) | KR100781864B1 (ko) |
CN (2) | CN1817883B (ko) |
AR (2) | AR032335A1 (ko) |
AT (2) | ATE320430T1 (ko) |
AU (4) | AU2001262874B2 (ko) |
BG (3) | BG65837B1 (ko) |
BR (1) | BR0111328A (ko) |
CA (1) | CA2408596C (ko) |
CY (1) | CY1113047T1 (ko) |
CZ (2) | CZ304347B6 (ko) |
DE (1) | DE60117972T2 (ko) |
DK (2) | DK1493745T3 (ko) |
EE (1) | EE05222B1 (ko) |
ES (2) | ES2384708T3 (ko) |
GB (1) | GB0013407D0 (ko) |
HK (2) | HK1052347B (ko) |
HU (2) | HU229374B1 (ko) |
IL (4) | IL152777A0 (ko) |
IS (2) | IS2609B (ko) |
MX (1) | MXPA02011795A (ko) |
MY (2) | MY148652A (ko) |
NO (3) | NO323780B1 (ko) |
NZ (1) | NZ522638A (ko) |
PH (1) | PH12011000127A1 (ko) |
PL (2) | PL359172A1 (ko) |
PT (2) | PT1493745E (ko) |
RU (3) | RU2325391C2 (ko) |
SG (1) | SG135965A1 (ko) |
SI (2) | SI1493745T1 (ko) |
SK (1) | SK287817B6 (ko) |
UA (1) | UA73181C2 (ko) |
WO (1) | WO2001092262A1 (ko) |
ZA (1) | ZA200209324B (ko) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
GB0013407D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
GB0013488D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Chemical compound |
JP4298212B2 (ja) * | 2002-03-29 | 2009-07-15 | 大日本印刷株式会社 | 塩酸エピナスチン高融点型結晶の製造法 |
WO2008024044A1 (en) * | 2006-08-21 | 2008-02-28 | Astrazeneca Ab | Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate |
TWI482772B (zh) * | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含***并[4,5-d]嘧啶衍生物之組合物 |
US7566722B2 (en) * | 2006-10-31 | 2009-07-28 | Janssen Pharmaceutica, N.V. | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists |
CN103071154A (zh) * | 2007-04-13 | 2013-05-01 | 千年药品公司 | 用起因子xa抑制剂作用的化合物的组合抗凝治疗 |
TWI496776B (zh) * | 2007-11-15 | 2015-08-21 | Astrazeneca Ab | 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法 |
UA100864C2 (uk) * | 2007-12-03 | 2013-02-11 | Астразенека Аб | Спосіб лікування або запобігання аневризмі черевної аорти |
MX2011002505A (es) | 2008-09-09 | 2011-04-07 | Astrazeneca Ab | Un proceso para preparar [1s-[1-alfa, 2-alfa, 3-beta (1s*, 2r*) 5-beta] ] -3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propil tio) 3h-1, 2, 3-triazolo [4,5-d] pirimidin-3-il] -5-(2-hidroxietoxi) ciclopentan-1, 2-diol y sus intermediarios. |
EP2459564B1 (en) | 2009-07-27 | 2016-09-07 | Auspex Pharmaceuticals, Inc. | Cyclopropyl modulators of p2y12 receptor |
JP2013512886A (ja) * | 2009-12-03 | 2013-04-18 | アストラゼネカ アクチボラグ | 血小板の凝集阻害剤トリアゾロ[4,5−d]ピリミジン共結晶 |
EP2515871B1 (en) | 2009-12-23 | 2015-09-23 | ratiopharm GmbH | Solid pharmaceutical dosage form of ticagrelor |
CZ2011229A3 (cs) * | 2011-04-19 | 2012-08-15 | Zentiva, K.S. | Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy |
CA2836394A1 (en) | 2011-06-01 | 2012-12-06 | Astrazeneca Ab | Novel ticagrelor co - crystal |
EP2785716A1 (en) * | 2011-11-30 | 2014-10-08 | Actavis Group PTC EHF | Novel crystalline form of ticagrelor and process for the preparation thereof |
WO2013150495A2 (en) | 2012-04-05 | 2013-10-10 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
BR112014032085A2 (pt) | 2012-06-29 | 2017-06-27 | Zentiva Ks | solvato de ticagrelor, processos para a preparação de um solvato e para a preparação de um cocristal, cocristal de ticagrelor, e, usos de um solvato e de um cocristal |
US9284320B2 (en) | 2012-07-04 | 2016-03-15 | Lek Pharmaceuticals D.D. | Ticagrelor adducts with divalent metal salts |
CZ2012705A3 (cs) * | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
CN103772393B (zh) * | 2012-10-18 | 2017-08-04 | 博瑞生物医药(苏州)股份有限公司 | 替卡格雷的晶型及其制备方法 |
WO2014083139A1 (en) * | 2012-11-29 | 2014-06-05 | Actavis Group Ptc Ehf | Novel amorphous form of ticagrelor |
CN103848836B (zh) * | 2012-12-07 | 2016-08-03 | 天津市汉康医药生物技术有限公司 | 替卡格雷倍半水合物及其制备方法 |
WO2014118808A2 (en) * | 2013-02-04 | 2014-08-07 | Hetero Research Foundation | Ticagrelor solid dispersion |
CZ307217B6 (cs) | 2013-03-14 | 2018-04-04 | Zentiva, K.S. | Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru |
IN2013MU01111A (ko) * | 2013-03-25 | 2015-05-01 | Glenmark Generics Ltd | |
CN104098570A (zh) * | 2013-04-07 | 2014-10-15 | 杭州领业医药科技有限公司 | 替卡格雷晶型及其制备方法和用途 |
CN104098572A (zh) * | 2013-04-08 | 2014-10-15 | 博瑞生物医药技术(苏州)有限公司 | 替卡格雷共晶型 |
CN107573333B (zh) * | 2013-04-10 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
EP2813216A1 (en) | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Stabilized amorphous ticagrelor |
WO2014170026A1 (en) | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Stabilized amorphous ticagrelor |
EP3003276A1 (en) | 2013-05-29 | 2016-04-13 | ratiopharm GmbH | Solid pharmaceutical dosage form |
CN106496235A (zh) * | 2013-06-03 | 2017-03-15 | 杭州领业医药科技有限公司 | 结晶形态的***[4,5‑d]嘧啶化合物及其制备方法和用途 |
EP3004113A2 (en) * | 2013-06-04 | 2016-04-13 | Dr. Reddy's Laboratories Ltd. | Preparation of ticagrelor |
EP2816043A1 (en) | 2013-06-21 | 2014-12-24 | LEK Pharmaceuticals d.d. | Spherical ticagrelor particles |
WO2015001489A1 (en) * | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of ticagrelor |
CN104341423B (zh) * | 2013-08-02 | 2017-03-01 | 上海京新生物医药有限公司 | 替格瑞洛的一水合物及其制备方法与在制药中的应用 |
CN104370912A (zh) * | 2013-08-13 | 2015-02-25 | 开原亨泰制药股份有限公司 | 替卡格雷多晶型体及其制备方法 |
WO2015037016A2 (en) * | 2013-09-10 | 2015-03-19 | Laurus Labs Private Limited | An improved process for the preparation of ticagrelor and intermediates thereof |
CZ2013866A3 (cs) | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
CN104650085A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 替卡格雷倍半水合物化合物 |
CN103601726B (zh) * | 2013-12-02 | 2016-09-28 | 浙江大学 | 两种替格瑞洛药物共晶及其制备方法 |
CN104710425B (zh) * | 2013-12-16 | 2019-06-14 | 石药集团中奇制药技术(石家庄)有限公司 | 一种替格瑞洛新结晶及其制备方法 |
CN104650091B (zh) * | 2014-01-24 | 2016-10-05 | 福州乾正药业有限公司 | 替格瑞洛的微粉化及其晶型,以及制备方法和药物应用 |
CN104940204A (zh) * | 2014-03-27 | 2015-09-30 | 广东东阳光药业有限公司 | 一种替格瑞洛固体制剂及其制备方法 |
WO2015162537A1 (en) * | 2014-04-23 | 2015-10-29 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of ticagrelor |
WO2015162630A1 (en) | 2014-04-25 | 2015-10-29 | Anlon Chemical Research Organization | Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis. |
CN105315282B (zh) * | 2014-07-15 | 2018-09-21 | 博瑞生物医药(苏州)股份有限公司 | 一种制备替卡格雷无定型的方法 |
WO2016016907A1 (en) * | 2014-08-01 | 2016-02-04 | Msn Laboratories Private Limited | Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol |
US10017515B2 (en) | 2014-08-11 | 2018-07-10 | Sun Pharmaceutical Industries Limited | Stable amorphous ticagrelor and a process for its preparation |
CN104193747B (zh) * | 2014-08-12 | 2016-05-11 | 许彩霞 | 替卡格雷无定形的制备 |
WO2016116942A1 (en) | 2015-01-20 | 2016-07-28 | Anlon Chemical Research Organization | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin |
CN105968113B (zh) * | 2015-03-12 | 2019-06-07 | 四川海思科制药有限公司 | 一种***并嘧啶衍生物及其应用 |
WO2017072790A1 (en) * | 2015-10-26 | 2017-05-04 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of ticagrelor |
WO2017118633A1 (en) * | 2016-01-05 | 2017-07-13 | Amneal Pharmaceuticals Company Gmbh | Crystalline form of ticagrelor |
CN107595789B (zh) | 2016-04-21 | 2021-01-15 | 阿斯利康(瑞典)有限公司 | 口腔崩解片 |
US10905691B2 (en) | 2016-09-09 | 2021-02-02 | Université de Liège | Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection |
DK3292867T3 (da) * | 2016-09-09 | 2019-07-22 | Univ Liege | Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion |
KR101916956B1 (ko) | 2016-12-13 | 2018-11-08 | 보령제약 주식회사 | 티카그렐러의 신규한 고체 형태 및 이의 제조방법 |
WO2018178997A1 (en) | 2017-03-31 | 2018-10-04 | Natco Pharma Limited | Novel crystalline form of ticagrelor |
WO2019127294A1 (zh) * | 2017-12-29 | 2019-07-04 | 浙江天宇药业股份有限公司 | 一种纯化替格瑞洛的方法 |
EP3761965A1 (en) | 2018-03-08 | 2021-01-13 | Pharmaceutical Oriented Services Ltd | Ticagrelor-containing tablet formulation |
EA202190328A1 (ru) | 2018-07-27 | 2021-07-01 | КРКА, д.д., НОВО МЕСТО | Фармацевтическая композиция, содержащая тикагрелор |
CN110194771A (zh) * | 2019-05-08 | 2019-09-03 | 北京济美堂医药研究有限公司 | 一种替格瑞洛药用ii晶型的制备方法 |
CN114634489B (zh) * | 2022-04-19 | 2023-07-04 | 奎马特里克斯有限公司 | 结晶形式 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
PL182680B1 (pl) * | 1995-07-11 | 2002-02-28 | Astrazeneca Ab | Nowe inhibitory skupiania się płytek krwi |
ATE213245T1 (de) * | 1996-12-20 | 2002-02-15 | Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente | |
TW530058B (en) | 1997-07-22 | 2003-05-01 | Astra Pharma Prod | Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation |
WO1999005150A1 (en) * | 1997-07-25 | 1999-02-04 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
TWI229674B (en) * | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
SE9904129D0 (sv) * | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
GB0013488D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Chemical compound |
GB0013407D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
-
2000
- 2000-06-02 GB GBGB0013407.2A patent/GB0013407D0/en not_active Ceased
-
2001
- 2001-05-22 AR ARP010102432A patent/AR032335A1/es unknown
- 2001-05-31 SG SG200500599-6A patent/SG135965A1/en unknown
- 2001-05-31 PL PL01359172A patent/PL359172A1/xx not_active IP Right Cessation
- 2001-05-31 SI SI200131013T patent/SI1493745T1/sl unknown
- 2001-05-31 EP EP10182133A patent/EP2292622A1/en not_active Withdrawn
- 2001-05-31 HU HU0302284A patent/HU229374B1/hu unknown
- 2001-05-31 AT AT01937109T patent/ATE320430T1/de active
- 2001-05-31 JP JP2002500875A patent/JP5036947B2/ja not_active Expired - Lifetime
- 2001-05-31 BR BR0111328-3A patent/BR0111328A/pt not_active Application Discontinuation
- 2001-05-31 NZ NZ522638A patent/NZ522638A/en not_active IP Right Cessation
- 2001-05-31 AU AU2001262874A patent/AU2001262874B2/en not_active Expired
- 2001-05-31 PT PT04015299T patent/PT1493745E/pt unknown
- 2001-05-31 UA UA20021210808A patent/UA73181C2/uk unknown
- 2001-05-31 AU AU6287401A patent/AU6287401A/xx active Pending
- 2001-05-31 MY MYPI20092026A patent/MY148652A/en unknown
- 2001-05-31 ES ES04015299T patent/ES2384708T3/es not_active Expired - Lifetime
- 2001-05-31 RU RU2002135589/04A patent/RU2325391C2/ru active
- 2001-05-31 PL PL392882A patent/PL392882A1/pl not_active Application Discontinuation
- 2001-05-31 MX MXPA02011795A patent/MXPA02011795A/es active IP Right Grant
- 2001-05-31 SK SK1685-2002A patent/SK287817B6/sk not_active IP Right Cessation
- 2001-05-31 PT PT01937109T patent/PT1289992E/pt unknown
- 2001-05-31 CN CN2006100025095A patent/CN1817883B/zh not_active Expired - Lifetime
- 2001-05-31 EE EEP200200665A patent/EE05222B1/xx unknown
- 2001-05-31 IL IL15277701A patent/IL152777A0/xx unknown
- 2001-05-31 DE DE60117972T patent/DE60117972T2/de not_active Expired - Lifetime
- 2001-05-31 MY MYPI20012578A patent/MY140674A/en unknown
- 2001-05-31 US US10/296,990 patent/US20030181469A1/en not_active Abandoned
- 2001-05-31 EP EP04015299.3A patent/EP1493745B2/en not_active Expired - Lifetime
- 2001-05-31 DK DK04015299.3T patent/DK1493745T3/da active
- 2001-05-31 CN CNB018105823A patent/CN1247583C/zh not_active Expired - Lifetime
- 2001-05-31 EP EP01937109A patent/EP1289992B1/en not_active Expired - Lifetime
- 2001-05-31 CZ CZ2002-3918A patent/CZ304347B6/cs not_active IP Right Cessation
- 2001-05-31 HU HU1300386A patent/HU230471B1/hu unknown
- 2001-05-31 CA CA2408596A patent/CA2408596C/en not_active Expired - Lifetime
- 2001-05-31 KR KR1020027016379A patent/KR100781864B1/ko active IP Right Review Request
- 2001-05-31 SI SI200130541T patent/SI1289992T1/sl unknown
- 2001-05-31 ES ES01937109T patent/ES2259031T3/es not_active Expired - Lifetime
- 2001-05-31 CZ CZ2012-293A patent/CZ307468B6/cs not_active IP Right Cessation
- 2001-05-31 AT AT04015299T patent/ATE555115T1/de active
- 2001-05-31 WO PCT/SE2001/001239 patent/WO2001092262A1/en active Application Filing
- 2001-05-31 DK DK01937109T patent/DK1289992T3/da active
-
2002
- 2002-11-11 IL IL152777A patent/IL152777A/en active IP Right Grant
- 2002-11-15 IS IS6623A patent/IS2609B/is unknown
- 2002-11-15 ZA ZA200209324A patent/ZA200209324B/en unknown
- 2002-11-28 BG BG107331A patent/BG65837B1/bg unknown
- 2002-11-29 NO NO20025756A patent/NO323780B1/no not_active IP Right Cessation
-
2003
- 2003-06-24 HK HK03104536.0A patent/HK1052347B/zh not_active IP Right Cessation
-
2005
- 2005-06-16 HK HK05105060.9A patent/HK1073101A1/xx not_active IP Right Cessation
- 2005-08-30 RU RU2005127356/04A patent/RU2418802C2/ru active Protection Beyond IP Right Term
- 2005-10-03 US US11/240,801 patent/US7265124B2/en not_active Expired - Lifetime
-
2007
- 2007-03-05 AU AU2007200958A patent/AU2007200958B2/en active Active
- 2007-03-23 NO NO20071547A patent/NO332306B1/no not_active IP Right Cessation
- 2007-08-24 US US11/892,597 patent/US20070293513A1/en not_active Abandoned
- 2007-11-19 IL IL187482A patent/IL187482A/en active IP Right Grant
-
2008
- 2008-07-24 AR ARP080103205A patent/AR068086A2/es unknown
-
2009
- 2009-06-02 IS IS8825A patent/IS3019B/is unknown
- 2009-08-12 BG BG10110440A patent/BG66332B1/bg unknown
- 2009-12-07 IL IL202582A patent/IL202582A/en active IP Right Grant
-
2010
- 2010-12-10 RU RU2010150799/04A patent/RU2010150799A/ru not_active Application Discontinuation
- 2010-12-24 AU AU2010257449A patent/AU2010257449B2/en not_active Expired
-
2011
- 2011-04-19 PH PH12011000127A patent/PH12011000127A1/en unknown
- 2011-08-18 BG BG10111017A patent/BG111017A/bg unknown
-
2012
- 2012-05-01 JP JP2012104575A patent/JP5684192B2/ja not_active Expired - Lifetime
- 2012-05-14 NO NO20120595A patent/NO333289B1/no not_active IP Right Cessation
- 2012-06-21 CY CY20121100559T patent/CY1113047T1/el unknown
-
2014
- 2014-04-07 JP JP2014078665A patent/JP2014129423A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100781864B1 (ko) | 트리아졸로(4,5-d)피리미딘 화합물의 신규 결정형 및비결정형 | |
AU2001262874A1 (en) | New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound | |
TWI330082B (en) | Crystalline form of triazolo(4,5-d)pyrimidine compound and method of preparing the same | |
TW201034672A (en) | Mixture of crystalline forms of triazolo (4,5-D) pyrimidine compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20121031 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131101 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141107 Year of fee payment: 8 |
|
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J501 | Disposition of invalidation of trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150327 Effective date: 20160323 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150314 Effective date: 20160323 |
|
FPAY | Annual fee payment |
Payment date: 20161028 Year of fee payment: 10 |
|
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100001440; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001347; TRIAL DECISION FOR INVALIDATION REQUESTED 20150326 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001349; TRIAL DECISION FOR INVALIDATION REQUESTED 20150326 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001348; TRIAL DECISION FOR INVALIDATION REQUESTED 20150326 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001355; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100000946; TRIAL DECISION FOR INVALIDATION REQUESTED 20150313 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100000949; TRIAL DECISION FOR INVALIDATION REQUESTED 20150313 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100000948; TRIAL DECISION FOR INVALIDATION REQUESTED 20150313 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001351; TRIAL DECISION FOR INVALIDATION REQUESTED 20150326 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100000944; TRIAL DECISION FOR INVALIDATION REQUESTED 20150313 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001425; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001439; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001341; TRIAL DECISION FOR INVALIDATION REQUESTED 20150326 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001350; TRIAL DECISION FOR INVALIDATION REQUESTED 20150326 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001354; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100000952; TRIAL DECISION FOR INVALIDATION REQUESTED 20150313 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001438; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100000939; TRIAL DECISION FOR INVALIDATION REQUESTED 20150313 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100000943; TRIAL DECISION FOR INVALIDATION REQUESTED 20150313 Effective date: 20170323 Free format text: TRIAL NUMBER: 2015100001386; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170323 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100001458; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170403 Free format text: TRIAL NUMBER: 2015100001542; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170403 Free format text: TRIAL NUMBER: 2015100001455; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170403 Free format text: TRIAL NUMBER: 2015100000942; TRIAL DECISION FOR INVALIDATION REQUESTED 20150313 Effective date: 20170403 Free format text: TRIAL NUMBER: 2015100001346; TRIAL DECISION FOR INVALIDATION REQUESTED 20150326 Effective date: 20170403 Free format text: TRIAL NUMBER: 2015100001564; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170403 Free format text: TRIAL NUMBER: 2015100001463; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170403 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100003753; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150701 Effective date: 20170622 |